Investigating the Impact of SN-38 on Mouse Brain Metabolism Based on Metabolomics
Xiaodong Zhu,Ya Huang,Jia Ding,Jianguo Liu,Changmeng Cui,Guangkui Han
DOI: https://doi.org/10.2147/dddt.s457698
IF: 4.3188
2024-06-21
Drug Design Development and Therapy
Abstract:Xiaodong Zhu, 1 Ya Huang, 2 Jia Ding, 1 Jianguo Liu, 1 Changmeng Cui, 1 Guangkui Han 1 1 Department of Neurosurgery, Affiliated Hospital of Jining Medical University, Jining, 272000, People's Republic of China; 2 College of Traditional Chinese Medicine, Shandong Polytechnic College, Jining, 272000, People's Republic of China Correspondence: Guangkui Han, Department of Neurosurgery, Affiliated Hospital of Jining Medical University, 89 Guhuai Road, Jining, Shandong, 272000, People's Republic of China, Tel +8618266808351, Email Purpose: SN-38 (7-ethyl-10-hydroxycamptothecin), the active metabolite of irinotecan, has been extensively studied in drug delivery systems. However, its impact on neural metabolism remains unclear. This study aims to investigate the toxic effects of SN-38 on mouse brain metabolism. Methods: Male mice were divided into an SN-38 group and a control group. The SN-38 group received SN-38 (20 mg/kg/day) via intraperitoneal injection, while the control group was given an equal volume of a blank solvent mixture (DMSO and saline, ratio 1:9). Gas chromatography-mass spectrometry (GC-MS) was employed to analyze differential metabolites in the cortical and hippocampal regions of the SN-38-treated mice. Results: SN-38 induced metabolic disturbances in the central nervous system. Eighteen differential metabolites were identified in the hippocampus and twenty-four in the cortex, with six common to both regions. KEGG pathway enrichment analysis revealed statistically significant alterations in six metabolic pathways in the hippocampus and ten in the cortex (P< 0.05). Conclusion: This study is the first to demonstrate the neurotoxicity of SN-38 in male mice through metabolomics. Differential metabolites in the hippocampal and cortical regions were closely linked to purine metabolism, pyrimidine metabolism, amino acid metabolism, and glyceride metabolism, indicating disruptions in the blood-brain barrier, energy metabolism, and central signaling pathways. Keywords: SN-38 (7-ethyl-10-hydroxycamptothecin), biomarker, gas chromatography mass spectrometry, metabolomics, toxicity mechanism Ethyl-10-hydroxycamptothecin (SN-38) is the active metabolite of irinotecan (camptothecin-11, also known as hydrochloride irinotecan). Irinotecan, a broad-spectrum cytotoxic anticancer drug, is widely used to treat various solid tumors and is frequently combined with other chemotherapeutic agents in treating cancers of the central nervous system (CNS).SN-38's antitumor activity is 100 to 1000 times more potent than CPT-11, leading to its extensive study in various drug delivery and controlled release systems. 1 Several SN38 prodrugs, including DTS108, EZN-2208, and SN38 antibody-drug conjugates (ADCs) such as IMMU132 and IMMU130, are currently in clinical trials. 2 Previously, our team developed an effective antitumor drug release system, the SN-38 loaded PCL/GT electrospun film, and investigated its cytotoxicity against gliomas. 3 The central mechanism of SN-38's anti-tumor activity involves inhibiting DNA topoisomerase I, resulting in DNA damage and cell death in rapidly proliferating normal cells, including bone marrow and intestinal basal cells. Studies have reported common hematologic and gastrointestinal side effects in cancer patients treated with Irinotecan. 4 Rarer toxicities, including articulatory disorders, severe systemic weakness, paralysis, and aphasia induced by irinotecan, have also been reported. 5 However, research on SN-38's effects on brain tissue is limited. Thus, the aim of this experiment is to thoroughly evaluate the neurotoxicity of SN-38 by examining its metabolite levels in the hippocampus and cerebral cortex, and to initially explore the specific mechanisms of SN-38-induced toxicity. Metabolomics plays a crucial role in the realm of systems biology. By combining it with other omics data such as genomics, transcriptomics, and proteomics, a more holistic molecular profile is achieved. This amalgamation offers a deeper understanding of various states such as disease pathology, pharmacological impacts, and responses to stress, while revealing underlying molecular processes. The use of multi-omics integration is prevalent across various domains, encompassing fundamental medical science, clinical diagnostics, pharmaceutical innovation, agricultural enhancement, and research into stress tolerance. 6–8 Building on neurotissue engineering research, our team employed an established metabolomics research platform to determine the overall impact of SN-38 on brain metabolites and metabolic pathways. This approach clarified the metabolic profile following SN-38 exposure and offere -Abstract Truncated-
pharmacology & pharmacy,chemistry, medicinal